Literature DB >> 30742828

Life-threatening complications among women with severe ovarian hyperstimulation syndrome.

Jessica Selter1, Timothy Wen2, Katherine L Palmerola3, Alexander M Friedman2, Zev Williams3, Eric J Forman3.   

Abstract

BACKGROUND: Ovarian hyperstimulation syndrome is a potentially life-threatening clinical condition.
OBJECTIVE: The objective of this study was to evaluate risk factors for life-threatening complications for patients with severe ovarian hyperstimulation syndrome in a United States nationwide sample.
MATERIALS AND METHODS: Ovarian hyperstimulation syndrome admissions from 2002 to 2011 from the Nationwide Inpatient Sample were included in this study. The association between patient and hospital factors and life-threatening complications (deep vein thrombosis/pulmonary embolism, acute respiratory distress syndrome, acute renal failure, intubation), nonroutine discharge (discharge to skilled nursing facility, transfer hospital), prolonged length of stay, and total hospital charges were analyzed. Survey-adjusted multivariable logistic regression analyses were performed for these outcomes, controlling for risk factors, with adjusted odds ratios with 95% confidence intervals as the measures of effect.
RESULTS: A total of 11,562 patients were hospitalized with severe ovarian hyperstimulation syndrome from 2002 to 2011. The majority were white (55.7%), with private insurance (87.7%), aged 25-39 years (84.6%), and hospitalized in an urban location (95%). In all, 19.3% of patients had medical comorbidities including hypertension, diabetes, obesity, hypothyroidism, and anemia. Life-threatening complications occurred in 4.4% of patients (deep vein thrombosis/pulmonary embolism, 2.2%; acute renal failure; acute respiratory distress syndrome, 0.9%; intubation, 0.5%). Patients ≥40 years old (odds ratio, 4.02; 95% confidence interval, 1.37, 11.76), those with comorbidities (odds ratio, 2.29; 95% confidence interval, 1.46, 3.57), and African American patients (odds ratio, 2.15; 95% confidence interval, 1.25, 3.70) were more likely to develop life-threatening conditions. Patients with medical comorbidities (odds ratio, 0.39; 95% confidence interval, 0.24, 0.63) were also less likely to be routinely discharged from the hospital. Adjusting for patient and hospital demographics, patients with comorbidities were more likely to develop deep vein thrombosis/pulmonary embolism (adjusted odds ratio, 2.44; 95% confidence interval, 1.28, 4.65) and acute renal failure (adjusted odds ratio, 2.26; 95% confidence interval, 1.21, 4.23). Patients who developed life-threatening complications had longer hospital length of stay (adjusted odds ratio, 3.72; 95% confidence interval, 2.28, 6.07) and higher hospital costs (adjusted odds ratio, 5.20; 95% confidence interval, 3.22,8.39).
CONCLUSION: Patients with common medical comorbidities are at higher risk for life-threatening complications in the setting of severe ovarian hyperstimulation syndrome. Furthermore, these complications are associated with high hospital costs and hospital burden. Given the increasing number of in vitro fertilization patients with medical comorbidities, closer monitoring of at-risk patients may be indicated. As assisted reproductive technology practice changes in recent years with strategies designed to reduce ovarian hyperstimulation syndrome risk, future studies are needed to assess the impact of these changes on hospitalization and complication risk.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ovarian hyperstimulation syndrome; severe morbidity

Mesh:

Year:  2019        PMID: 30742828     DOI: 10.1016/j.ajog.2019.02.009

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Sudden death of an egg donor during oocyte retrieval due to ovarian hyperstimulation syndrome.

Authors:  Swati Tyagi; Asit Ranjan Mridha; Chittaranjan Behera
Journal:  Autops Case Rep       Date:  2022-05-27

2.  Rescue In Vitro Maturation in Polycystic Ovarian Syndrome Patients Undergoing In Vitro Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study.

Authors:  Muhammad Fatum; Marie Eve Bergeron; Caroline Ross; Anni Ding; Ayesha Bhevan; Karen Turner; Tim Child
Journal:  Int J Fertil Steril       Date:  2020-07-15

3.  Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology

Authors:  Cengiz Şanlı; Remzi Atılgan; Tuncay Kuloğlu; Şehmus Pala; Bilge Aydın Türk; Hasan Burak Keser; Nevin İlhan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

4.  Immunoglobulin Treatment in Severe Ovarian Hyperstimulation Syndrome.

Authors:  Gemma Grau Gómez; Oriol Giménez Campanario; Nuria Pons Serra; Mireia Cairó Llobell; Pedro Almagro Mena
Journal:  Eur J Case Rep Intern Med       Date:  2019-10-02

Review 5.  Spontaneous ovarian hyperstimulation syndrome in a nonpregnant female patient: a case report and literature review.

Authors:  Wei Chai; Hongyu He; Fei Li; Wenlei Zhang; Chao He
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.